Literature DB >> 21309737

Differential expression of monocyte/macrophage- selective markers in human idiopathic pulmonary fibrosis.

Bela Desai1, Jeanine Mattson, Harman Paintal, Manjari Nathan, Fran Shen, Maribel Beaumont, Maria-Christina Malinao, Ying Li, James Canfield, Beth Basham, Rene de Waal Malefyt, Terrill McClanahan, Ganesh Krishna, Robert Fick.   

Abstract

Idiopathic interstitial pneumonias are a group of idiopathic interstitial lung diseases of which idiopathic pulmonary fibrosis (IPF) is the lesion of usual interstitial pneumonia. Although the pathogenic mechanisms remain incompletely understood, disease-specific changes in blood, a readily accessible biospecimen, have not been fully characterized. To identify biomarkers from blood and sera, the immune status of IPF patients and control subjects without structural lung disease was quantified by measuring cell surface markers, mRNA levels, and serum proteins. Statistically significant differences in cellular and molecular markers were observed between the 2 groups. The cytokine receptor IL-17RB was significantly higher in CD14+ peripheral blood mononuclear cells (PBMCs) from IPF patients, whereas expression of the chemokine receptor CXCR4 was lower. Gene expression analyses identified 18 differentially expressed genes out of 195 selected. Of these, EMR1, CCR3, UPAR, FCGR2A, OPN, CEACAM3, CD16a, CD18, CD11b, LTF, and LCN2 were up-regulated, whereas IL-17RB, IL-10, PDGFA, CD301/Clec10a, CD25/IL-2RA, IL-23p19, and IL-15 were down-regulated in IPF. Differentially regulated genes were in the functional areas of inflammation and cell signaling. Serum levels of UPAR and OPN were higher in IPF. These observations reveal significant differences in cell and molecular markers involved in monocyte/macrophage activation and migration, and suggest a role for IL-17RB in IPF.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21309737     DOI: 10.3109/01902148.2010.538132

Source DB:  PubMed          Journal:  Exp Lung Res        ISSN: 0190-2148            Impact factor:   2.459


  16 in total

Review 1.  Influences of innate immunity, autophagy, and fibroblast activation in the pathogenesis of lung fibrosis.

Authors:  David N O'Dwyer; Shanna L Ashley; Bethany B Moore
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-07-29       Impact factor: 5.464

2.  A novel seven-gene risk profile in BALF to identify high-risk patients with idiopathic pulmonary fibrosis.

Authors:  Ziliang Hou; Dan Peng; Jingjing Yang; Shuai Zhang; Jinxiang Wang
Journal:  J Thorac Dis       Date:  2022-05       Impact factor: 3.005

3.  Phenotypic characterization of lung macrophages in asthmatic patients: overexpression of CCL17.

Authors:  Karl J Staples; Timothy S C Hinks; Jon A Ward; Victoria Gunn; Caroline Smith; Ratko Djukanović
Journal:  J Allergy Clin Immunol       Date:  2012-09-14       Impact factor: 10.793

4.  Mesenchymal stromal cell exosomes prevent and revert experimental pulmonary fibrosis through modulation of monocyte phenotypes.

Authors:  Nahal Mansouri; Gareth R Willis; Angeles Fernandez-Gonzalez; Monica Reis; Sina Nassiri; S Alex Mitsialis; Stella Kourembanas
Journal:  JCI Insight       Date:  2019-11-01

5.  Common and distinct mechanisms of induced pulmonary fibrosis by particulate and soluble chemical fibrogenic agents.

Authors:  Jie Dong; Xiaoqing Yu; Dale W Porter; Lori A Battelli; Michael L Kashon; Qiang Ma
Journal:  Arch Toxicol       Date:  2015-09-07       Impact factor: 5.153

6.  Extracellular Vesicle Surface Signatures in IPF Patients: A Multiplex Bead-Based Flow Cytometry Approach.

Authors:  Miriana d'Alessandro; Piera Soccio; Laura Bergantini; Paolo Cameli; Giulia Scioscia; Maria Pia Foschino Barbaro; Donato Lacedonia; Elena Bargagli
Journal:  Cells       Date:  2021-04-28       Impact factor: 6.600

7.  Measurement of MMP-9 and -12 degraded elastin (ELM) provides unique information on lung tissue degradation.

Authors:  Helene Skjøt-Arkil; Rikke E Clausen; Quoc Hai Trieu Nguyen; Yaguo Wang; Qinlong Zheng; Fernando J Martinez; Cory M Hogaboam; Meilan Han; Lloyd B Klickstein; Martin R Larsen; Arkadiusz Nawrocki; Diana J Leeming; Morten A Karsdal
Journal:  BMC Pulm Med       Date:  2012-07-20       Impact factor: 3.317

8.  Serological investigation of the collagen degradation profile of patients with chronic obstructive pulmonary disease or idiopathic pulmonary fibrosis.

Authors:  Diana J Leeming; Jannie M Sand; Mette J Nielsen; Federica Genovese; Fernando J Martinez; Cory M Hogaboam; Meilan K Han; Lloyd B Klickstein; Morten A Karsdal
Journal:  Biomark Insights       Date:  2012-09-13

9.  Potential role of the inflammasome-derived inflammatory cytokines in pulmonary fibrosis.

Authors:  Rupa Biswas; Melisa Bunderson-Schelvan; Andrij Holian
Journal:  Pulm Med       Date:  2011-06-02

10.  Antibody-mediated depletion of CCR10+EphA3+ cells ameliorates fibrosis in IPF.

Authors:  Miriam S Hohmann; David M Habiel; Milena S Espindola; Guanling Huang; Isabelle Jones; Rohan Narayanan; Ana Lucia Coelho; Justin M Oldham; Imre Noth; Shwu-Fan Ma; Adrianne Kurkciyan; Jonathan L McQualter; Gianni Carraro; Barry Stripp; Peter Chen; Dianhua Jiang; Paul W Noble; William Parks; John Woronicz; Geoffrey Yarranton; Lynne A Murray; Cory M Hogaboam
Journal:  JCI Insight       Date:  2021-06-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.